Medigen Biotechnology Corp. (TPEX 3176) today announced that the Natural Killer (NK) cell treatment plan, jointly submitted with E-Da Cancer Hospital, has been approved by the Ministry of Health and Welfare. Magicell®-NK (Trade name of NK product), is the resulted product of Medigen’s proprietary technology for the expansion and activation of NK cells, and the first NK cell therapy approved in Taiwan for cancer treatment according to the “Regulations Governing the Application of Specific Medical Examination Technique and Medical Device”. Under this special regulation, Magicell®-NK can be used for treating stage IV solid cancers, including colorectal cancer, lung cancer, breast cancer, liver cancer, head and neck cancer, prostate cancer and pancreatic cancer.
NK cells form the first line of defense of our innate immune system against cancer, aging and viral infection. They are the most effective killer cells of our immune system. Magicell®-NK technology, independently developed by Medigen, can efficiently increase the number and cytotoxic activity of NK cells, without any genetic modification or using any feeder cells. Such technology is expected to provide safer and more effective treatment option for cancer patient.
Based on the mission of guarding life and health of human beings, Medigen is devoted to developing a full range of cell therapy services, bringing convenience to patients in need. In fact, Medigen are collaborating with medical institutions from all over Taiwan. So far the cell therapy treatment plans have been submitted with 8 medical institutions: E-Da Cancer Hospital, Evergreen Health Clinic, Buddhist Tzu Chi General Hospital (Hualien), Doctor’s Doctor Clinic, Changhua Christian Hospital, Chi Mei Hospital (Liouying), Dr. Lobsang Clinic and Jen-Ai Hospital (Da-Li). Medigen expects that, once these treatment plans are approved, patients will be able to choose nearby medical institution for cell therapy treatment.